BIO has recently surged against the trend, marking a quiet revolution in longevity research driven by AI on the blockchain.
Written by: Nicky, Foresight News
The token BIO of Bio Protocol has recently shown impressive performance. According to Bitget data, the price of BIO started at $0.056 on August 6, 2025, and climbed to a peak of $0.2081 on August 22, with an increase of over 270% during this period.
Currently, the staking scale of BIO has reached approximately 174 million tokens, accounting for about 9.3% of the total circulating supply of 1.854 billion tokens. At the same time, BIO has been listed on several mainstream exchanges, including Binance, Coinbase, and Bithumb.
The DeSci craze at the end of 2024 lasted only a few months. After BIO was listed on Binance, its token performance was described as "disastrous," dropping from a historical high of $0.8 after its launch to around $0.05 by August 2025, a decline of over 90% from its peak. So what has revived BIO?
Looking back at the project's origins, on November 8, 2024, Binance Labs (now YZi Labs) announced an investment in Bio Protocol. Although the investment details were not disclosed, this move marked mainstream capital's recognition of the DeSci sector.
As a representative project in the DeSci sector, Bio Protocol's core goal is to "transform the funding and commercialization model of early biotechnology research," building a network of biotechnology DAOs.
By leveraging blockchain technology, it allows global scientists, patients, and investors to participate in new drug development, addressing the pain points of traditional research where "funding is concentrated in large pharmaceutical companies, and results are closed off." It helps global participants fund and collaborate on new drug development, especially for issues related to rare diseases, longevity research, and emerging health concerns.
On June 3, 2025, the DeSci project token PYTHIA began to rise, increasing from $0.0168 to $0.122 by August 14, with a growth of 626%.
On July 31, 2025, Coinbase simultaneously listed the tokens BIO and RSC from two DeSci projects, marking the return of DeSci to the Western mainstream cryptocurrency market.
Since then, the token VITA of the DeSci project VitaDAO has risen from $1.17 on August 1 to a high of $2.22 on August 22, with a total increase of 89%. The token NEURON of Cerebrum DAO also performed well in August, with an increase of over 180% this month. Meanwhile, the token CRYO of CryoDAO saw an increase of over 200%, and the token GROW of ValleyDAO increased by 76%, while the token HAIR of HairDAO rose by 67.5%. This indicates that DeSci is experiencing a revival.
Aubrai: How AI Scientists Are Rewriting the Rules of Longevity Research?
Entering 2025, Bio Protocol is accelerating its iteration. On August 21, Bio Protocol, in collaboration with VitaDAO, launched the first BioAgent Launch project, Aubrai, marking the official implementation of its "decentralized research agency" plan. This sale lasted only 24 hours, allowing users to participate by staking BioXP and investing in BIO tokens, with the token AUBRAI's TGE scheduled for August 25.
Currently, the tokenomics of AUBRAI has been announced, with a total supply of 2 million tokens. The token distribution is as follows: 20% for sale, 6% for liquidity pool, 15% for the treasury, 20.1% allocated to initial funders, 10% to the LEV Foundation, 22% to VitaDAO, and 6.9% to Bio Protocol.
Aubrai is based on data from the private laboratory of longevity research pioneer Dr. Aubrey de Grey, who proposed the "Strategies for Engineered Negligible Senescence" (SENS) aimed at preventing age-related diseases by repairing damage to aging cells in the human body. He holds a Bachelor's degree in Computer Science and a Ph.D. in Biology from the University of Cambridge and has authored works such as "Mitochondrial Free Radical Aging Theory" (1999) and "Ending Aging" (2007).
De Grey is currently the Chairman and Chief Scientific Officer of the LEV Foundation, which focuses on longevity research. Its flagship project, "Robust Mouse Rejuvenation," tests late-stage intervention therapy combinations through large-scale mouse lifespan experiments. These experiments, in collaboration with Ichor Life Sciences, emphasize damage repair methods while avoiding early interventions like gene editing to accelerate clinical translation to humans.
Another LEV project, "Transplants on Demand," explores tissue engineering and funds Keinice Bio's low-temperature preservation technology, using supercooled helium to achieve organ vitrification preservation. This avoids the toxicity issues of traditional cryoprotectants, aiming to provide "ready-to-use" young organ replacements to address organ failure caused by aging.
The LEV Foundation also supports the Alliance for Longevity Initiatives, a 501(c)(4) nonprofit organization aimed at promoting U.S. government policy support for longevity research. By collaborating with relevant experts, it seeks to raise public awareness of age-related chronic diseases and advocate for national funding.
Through these studies, its private laboratory has accumulated thousands of unpublished research notes, internal experimental data, and collective knowledge in the global longevity field. These "private research assets," previously limited to the core team, are now integrated by Aubrai as training data.
In practical applications, Aubrai has transformed the workflow of de Grey's team. It manages over a dozen complex longevity research projects, compressing manual reviews that originally took weeks into just a few days. It also identifies dosage conflicts, timing mismatches, and hidden biases, even discovering new issues that the team had not noticed.
According to the official roadmap, Aubrai has currently received joint funding from Bio Protocol and VitaDAO for the RMR2 pilot study, aimed at validating candidate interventions and optimizing administration methods; community scientists can experience its collaborative capabilities as a "co-scientist" through a closed beta CHAT UI. Meanwhile, the wallet supports a self-hosted EOA wallet built on the Coinbase Developer Platform, with limited transaction authorization features.
In future plans, Aubrai will launch a semi-autonomous agent in Q4 2025 (integrating Base AgentKit, supporting full transaction execution and financial autonomy) and open the FAILURE DB database (recording negative results and design flaws to avoid repeating mistakes), ultimately achieving "fully autonomous research" — a complete scientific output process from hypothesis generation, experimental design to wet lab execution and paper publication.
V2 Upgrade: Building an Efficient Cycle of "Research - Capital"
The implementation of Aubrai is supported by the V2 version of Bio Protocol. Its V2 version adopts the "launch and grow" concept, achieving sustainable growth through a community-driven launchpad:
Undervalued Launch: Referencing platforms like Pump.fun, the project's initial valuation is reduced to $205,000 FDV, with 37.5% of tokens sold directly, allowing each user to subscribe to a maximum of 0.5% of the total sale tokens;
Sustainable Liquidity: All funds raised (BIO tokens) after the launch will automatically generate an LP pool, combined with 12.5% of the supply tokens. A 1% fee will be charged on each transaction in the secondary market (70% goes to the project treasury, 30% to the protocol), forming a positive cycle of "active trading — increased research funding — advancement of results — renewed market interest";
Point Incentive Mechanism: Users can earn BioXP points through staking, governance voting, community dissemination, and participation in new launch projects, which can be used to participate in the quota subscription of undervalued projects.
The implementation of these mechanisms has allowed Bio Protocol to upgrade from a "research financing platform" to a "research ecosystem operating system," not only solving funding issues but also enhancing the efficiency of research result transformation through community incentives and automation tools.
The "Long-Termism" and Future of DeSci
The market performance of BIO and the launch of Aubrai have brought the DeSci sector back into the public eye. However, the challenges in this field have never disappeared: research cycles are long (even with Aubrai accelerating experiments, longevity therapies still require years to move from the lab to clinical trials), market patience is short (crypto investors are accustomed to "quick rises and falls"), and regulatory uncertainties (high compliance costs associated with human trials).
In this regard, Binance founder Zhao Changpeng candidly stated in an interview with Foresight News: "DeSci and meme coins are completely two extremes. DeSci projects have long cycles, while investors in the digital currency industry generally have shorter attention spans. Meme coins are very popular, and such projects are often overlooked. But in the long run, these projects contribute significantly to humanity and society, and I believe they will develop in the future, just not sure when."
免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。
